Company Profile
GH Research Stock Price, News & Analysis
- Ticker:
- GHRS
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- Ireland and listed in the U
Stock performance
27.75 USD (+1.72%)
Close
Last updated: July 27, 2026
1.71B USD
Market cap
Why the stock is moving
As of Jul 27, 2026, GHRS closed up 1.72% at $27.75. No new same-company headline was identified in the current news window.
Company overview
Business overview
GH Research is a neuroscience company developing psychedelic-inspired therapies for treatment-resistant depression and related disorders. Its work centers on novel CNS mechanisms and differentiated psychiatric care.
Geographic Base and Sector Classification
Headquartered in Ireland and listed in the U.S. as an ADR, GH Research has a global CNS-biotech profile.
Business Model Characteristics
The model depends on clinical data, regulatory progress, and the ability to translate novel CNS science into value.
Position Within the Biotechnology Landscape
GH Research is a high-catalyst CNS name whose valuation is highly sensitive to clinical and regulatory outcomes.
Future catalysts
The cleaner way to frame GH Research right now is around HV-106, HV-109, and the rest of its current pipeline. The most useful line from the latest update is Phase 2b results in TRD published in JAMA Psychiatry GH001-HV-106 study enrolment completed. That should keep the program at the center of the company narrative for now.
Recent news
The five most recent related feed items are shown below in reverse chronological order.
- 01
BrainStorm Appoints Former FDA Associate Commissioner Peter J. Pitts as Executive Chairman
BCLI · Source: Brainstorm Cell Therapeutics Inc.
- 02
Denali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026
DNLI · Source: Denali Therapeutics
- 03
Tonix Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 10, 2026
TNXP · Source: Tonix Pharmaceuticals
- 04
Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH
IKT · Source: Inhibikase Therapeutics
- 05
Pasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology (ESMO) Congress 2026
KTTA · Source: Pasithea Therapeutics
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of GH Research (GHRS)?
GH Research (GHRS) most recently closed at 27.75 USD, a +1.72% move versus the previous session.
What is the market cap of GH Research (GHRS)?
GH Research currently has a market capitalization of 1.71B USD on BioPharmSignal.
What does GH Research do?
GH Research is a neuroscience company developing psychedelic-inspired therapies for treatment-resistant depression and related disorders. Its work centers on novel CNS mechanisms and differentiated psychiatric care.
On which exchange is GHRS stock listed?
GH Research (GHRS) is associated with NASDAQ, Ireland and listed in the U, Biopharma.
What is HV-106?
The cleaner way to frame GH Research right now is around HV-106, HV-109, and the rest of its current pipeline.
Which conditions is GH Research targeting with HV-106?
GH Research is associated with neuroscience based on its company overview and current catalyst commentary.
How does GH Research describe recent progress with HV-106?
The cleaner way to frame GH Research right now is around HV-106, HV-109, and the rest of its current pipeline.
What is HV-109?
The cleaner way to frame GH Research right now is around HV-106, HV-109, and the rest of its current pipeline.